Scientists have developed a new model of bowel cancer that could reveal how cancer cells are resistant to immunotherapy drugs!

November 25, 2020 // -- Scientists from the Institute of Cancer Research in London, UK, have developed a sophisticated model system that may be able to simulate the most common bowel cancer and reveal how it evades immunotherapy; Preliminary findings from an ongoing study presented at the U.S. National Cancer Institute's virtual presentation in 2020 offer new insights into how bowel cancer develops resistance to the drug cibisatamab, a new immunotherapy drug developed by Roche Pharmaceuticals.
is the third most common type of cancer in the world, and although some bowel cancer patients can use immunotherapy drugs for treatment, the vast majority of cases do not respond to current immunotherapy.
the environment these intestinal cancer cells create in the patient's body inhibits the host immune system and eventually resists therapy, revealing in depth the molecular mechanisms that occur or hopefully helping more patients respond to immunotherapy.
Photo Source: The Institute of Cancer Research has developed a model of bowel cancer that simulates an immune system response, and scientists at the Cancer Institute in London, UK, have developed a new model of bowel cancer in the lab that simulates the immune response environment found in disease and patients, which may help scientists understand how bowel cancer is resistant to the drug cibisatamab.
Cibisatamab is an antibody-based drug that binds to both CD3 proteins on the surface of white blood cells and proteins called CEA on the surface of tumor cells, and clinical trials conducted by researchers in bowel cancer have shown some drug activity, but some tumors still have resistance to the drug.
The new model can extract cancer cells from the patient's body and build them into a three-dimensional structure, called PDOs, patient-derived organoids, which researchers can combine with white blood cells and single micro-environmental factors or tumor micro-environment cells. researchers at
drug cibisatamab tested the effects of the drug cibisatamab in this system, and researchers found preliminary results that were of great interest to them, and ultimately, the results may help guide the use of cibisatamab drugs and how they can be combined with other therapies to help treat patients;
Researcher Dr Maria Semiannikova said: 'I am delighted to be presenting my research project at the Virtual Exhibition at the National Cancer Institute, which, in collaboration with a major pharmaceutical company, has found a new clue to drug resistance to immunotherapy antibodies.
Finally, the researchers say cibisatamab is a highly promising immunotherapy drug, but not all bowel cancer patients react; the new model developed by the researchers in this study simulates real tumors and the micro-environment around them, which may help researchers quickly articulate how to effectively respond to antibiotic resistance in the lab.
() Reference: New bowel cancer model guangming how it avoids immunotherapy drugby Institute of Cancer Research